OTC: SOLTF - Sosei Group Corporation

Altı ay boyunca karlılık: -34.7%
Sektör: Healthcare

Promosyon programı Sosei Group Corporation

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis.

daha fazla ayrıntı
The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

EBITDA 273.3
EV/EBITDA -4.74
Industry Biotechnology
P/BV 0.0346
P/E 1.09
P/S 0.1604
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 1056.49
Див.доход ао 0
Дивиденд ао 1583.28
Сайт https://soseiheptares.com
Цена ао 10.53
Число акций ао 0.08252 млрд
Günlük fiyat değişimi: 0% (6.1575)
Haftalık fiyat değişimi: 0% (6.1575)
Aylık fiyat değişimi: -23.53% (8.052)
3 ayda fiyat değişimi: -32.7% (9.15)
Altı ayda fiyat değişimi: -34.7% (9.43)
Yıllık fiyat değişimi: -38.43% (10)
3 yılda fiyat değişimi: -63.61% (16.92)
5 yılda fiyat değişimi: -23.32% (8.03)
10 yılda fiyat değişimi: 0% (6.1575)
Yılbaşından bu yana fiyat değişimi: -8.78% (6.75)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 9 1
P/BV 0.0122 10
P/E 325.54 1
EV/EBITDA -550.44 0
Toplam: 4.25

Yeterlik

İsim Anlam Seviye
ROA, % -0.0325 0
ROE, % -0.0764 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0.5 5
Toplam: 1.31

Görev

İsim Anlam Seviye
Debt/EBITDA -1497.58 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -98.87 0
karlılık Ebitda, % -101.96 0
karlılık EPS, % -104.07 0
Toplam: 0
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Smallcap World Fund 1841200 2.06
Vanguard International Stock Index-Total Intl Stock Indx 997900 1.12
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 604000 0.68
iShares Core MSCI EAFE ETF 441300 0.49
iShares MSCI EAFE Small Cap ETF 284100 0.32
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 278200 0.31
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 149344 0.17
iShares Core MSCI Total International Stock ETF 129600 0.14
Vanguard International Stock Index-Pacific Stock Index 89400 0.1
iShares Core MSCI International Developed Markets ETF 62100 0.07



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Christopher Cargill Representative Executive Officer, President, CEO & Director 1.25M 1984 (41 yıl)
Mr. Hironoshin Nomura Executive Officer, Executive VP & CFO N/A 1983 (42 yıl)
Mr. Kieran Johnson F.C.A. Executive Officer, Executive VP & Chief Accounting Officer N/A 1969 (56 yıllar)
Mr. Toshihiro Maeda Executive VP & COO N/A 1979 (46 yıllar)
Mr. Kazuhiko Yoshizumi Executive Officer, Executive VP & Chief Compliance Officer N/A 1954 (71 yıl)
Shinichiro Nishishita VP of Investor Relations & Head of Regulatory Disclosures N/A
Stacey Southall Associate Director & Head of Biophysics N/A
Ms. Candelle Chong Executive Officer, Executive VP, CEO Office & Chief of Staff N/A 1989 (36 yıllar)
Dr. Satoshi Tanaka Exe. Off., Executive VP and President of Idorsia Pharmaceuticals Japan & Nxera Pharma Japan N/A 1957 (68 yıllar)
Dr. Shinichi Tamura Founder & Chairman of the Board 1949 (76 yıllar)

Adres: Japan, Tokyo -, PMO Hanzomon - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://soseiheptares.com